Rani Therapeutics Holdings logo

Rani Therapeutics HoldingsNASDAQ: RANI

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

30 July 2021

Next earnings report:

20 March 2025

Last dividends:

N/A

Next dividends:

N/A
$67.62 M
-89%vs. 3y high
39%vs. sector
-vs. 3y high
-vs. sector
-41%vs. 3y high
97%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | 8 min ago
$2.03-$0.05(-2.40%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

RANI Latest News

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants
globenewswire.com15 October 2024 Sentiment: POSITIVE

SAN JOSE, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 3,000,000 shares of Rani Therapeutics' Class A common stock (the “Common Stock”) and pre-funded warrants to purchase 333,333 shares of Common Stock, together with Series C common warrants to purchase up to an aggregate of 3,333,333 shares of Common Stock, in a registered direct offering. Each share of Common Stock (or pre-funded warrant) is being sold together with one Series C common warrant at a combined purchase price of $3.00. The Series C common warrants will have an exercise price of $3.00 per share and will expire 5 years from the date of issuance.

Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit
globenewswire.com08 October 2024 Sentiment: POSITIVE

SAN JOSE, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) --  Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company's Chief Executive Officer, Talat Imran, and Chief Financial Officer, Svai Sanford, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, October 17, 2024 from 11:30 am – 12:00 pm E.T. in Track 2.

Rani Therapeutics to Participate in August Investor Conferences
globenewswire.com29 July 2024 Sentiment: POSITIVE

SAN JOSE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in two upcoming investor conferences in August 2024. These conferences include:

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering
globenewswire.com22 July 2024 Sentiment: POSITIVE

SAN JOSE, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 2,800,000 shares of Rani Therapeutics' Class A common stock (the “Common Stock”) and pre-funded warrants to purchase 446,753 shares of Common Stock, together with Series A common warrants to purchase up to an aggregate of 3,246,753 shares of Common Stock and Series B common warrants to purchase up to an aggregate of 3,246,753 shares of Common Stock, in a registered direct offering. Each share of Common Stock and pre-funded warrant is being sold together with one Series A common warrant to purchase one share of Common Stock and one Series B common warrant to purchase one share of Common Stock at a combined purchase price of $3.08. The Series A common warrants and Series B common warrants will each have an exercise price of $3.08 per share, will each be exercisable 6 months from the date of issuance, and, in the case of Series A common warrants, will expire 18 months from the date of issuance, and in the case of Series B warrants, will expire five and a half years from the date of issuance.

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
GlobeNewsWire15 March 2024 Sentiment: POSITIVE

SAN JOSE, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2023 and provide a business update on Wednesday, March 20 after the close of trading. Rani's management team will host a conference call and webcast beginning at 4:30 p.m. ET.

What Makes Rani Therapeutics Holdings, Inc. (RANI) a New Buy Stock
Zacks Investment Research07 December 2023 Sentiment: POSITIVE

Rani Therapeutics Holdings, Inc. (RANI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Rani Therapeutics to Participate in August Investor Conferences
GlobeNewsWire04 August 2023 Sentiment: NEUTRAL

SAN JOSE, Calif., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in three upcoming investor conferences in August 2023. These conferences include:

Rani Therapeutics: Novel Drug Delivery System, Under-Covered And Early Stage
Seeking Alpha05 May 2023 Sentiment: POSITIVE

Rani Therapeutics Holdings, Inc. has an exciting oral drug delivery system for biologics. It has shown excellent early data in trials.

What type of business is Rani Therapeutics Holdings?

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

What sector is Rani Therapeutics Holdings in?

Rani Therapeutics Holdings is in the Healthcare sector

What industry is Rani Therapeutics Holdings in?

Rani Therapeutics Holdings is in the Biotechnology industry

What country is Rani Therapeutics Holdings from?

Rani Therapeutics Holdings is headquartered in United States

When did Rani Therapeutics Holdings go public?

Rani Therapeutics Holdings initial public offering (IPO) was on 30 July 2021

What is Rani Therapeutics Holdings website?

https://www.ranitherapeutics.com

Is Rani Therapeutics Holdings in the S&P 500?

No, Rani Therapeutics Holdings is not included in the S&P 500 index

Is Rani Therapeutics Holdings in the NASDAQ 100?

No, Rani Therapeutics Holdings is not included in the NASDAQ 100 index

Is Rani Therapeutics Holdings in the Dow Jones?

No, Rani Therapeutics Holdings is not included in the Dow Jones index

When was Rani Therapeutics Holdings the previous earnings report?

No data

When does Rani Therapeutics Holdings earnings report?

The next expected earnings date for Rani Therapeutics Holdings is 20 March 2025